Breast cancer is the most commonly diagnosed cancer among women worldwide. The
current pharmacological treatments for breast cancer have numerous adverse effects and …

Chemotherapy-induced peripheral neuropathy (CIPN) is a treatment-limiting adverse effect
of anticancer therapy that complicates the lifestyle of many cancer survivors. There is …

Clinicians should be aware of the potential for persistent TIPN and its impact on patients'
function and QOL. Future research should focus on large prospective studies with systematic …

Taxane‐based chemotherapy regimens are used as first‐line treatment for breast cancer.
Neurotoxicity, mainly taxane‐induced peripheral neuropathy (TIPN), remains the most …

Identifying patients at higher risk of chemotherapy-induced peripheral neuropathy (CIPN) is
a major unmet need given its high incidence, persistence, and detrimental effect on quality …

Purpose Peripheral neuropathy adversely affects the treatment process of cancer, and thus it
is important to reveal the factors leading to peripheral neuropathy and to take the necessary …

Background Improved breast cancer treatment has lengthened survival but also has long‐
term impacts. Lymphedema and peripheral neuropathy are treatment‐related sequelae that …

Objectives Neurological complications including pain are common after treatment for breast
cancer. This prospective study investigated the symptoms, intensity and interference of …

Sleep disturbance is common among women with breast cancer and is associated with
greater symptom distress and poorer outcomes. Yet, for the unique subgroup of young …

Treatment for breast cancer (BC) can lead to debilitating symptoms that can reduce
outcomes and quality of life (QoL). Symptom surveillance using a remote symptom …